{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:34:29Z","timestamp":1791581669392,"version":"4.3.4"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018231","name":"Aligning Science Across Parkinson's","doi-asserted-by":"publisher","award":["ASAP-000420"],"award-info":[{"award-number":["ASAP-000420"]}],"id":[{"id":"10.13039\/100018231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40263-024-01073-4","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T20:26:46Z","timestamp":1712176006000},"page":"315-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-7910","authenticated-orcid":false,"given":"Elisa","family":"Menozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-3966","authenticated-orcid":false,"given":"Anthony H. V.","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"4","key":"1073_CR1","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","volume":"99","author":"JF Cryan","year":"2019","unstructured":"Cryan JF, O\u2019Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877\u20132013.","journal-title":"Physiol Rev"},{"issue":"21","key":"1073_CR2","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","volume":"73","author":"R Savica","year":"2009","unstructured":"Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology. 2009;73(21):1752\u20138.","journal-title":"Neurology"},{"issue":"6645","key":"1073_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"2","key":"1073_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-013-1214-6","volume":"127","author":"D Hilton","year":"2014","unstructured":"Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, et al. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson\u2019s disease. Acta Neuropathol. 2014;127(2):235\u201341.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1073_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.25020","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov Disord. 2012;27(6):716\u20139.","journal-title":"Mov Disord"},{"issue":"20","key":"1073_CR6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1212\/WNL.0000000000002126","volume":"85","author":"FS Sprenger","year":"2015","unstructured":"Sprenger FS, Stefanova N, Gelpi E, Seppi K, Navarro-Otano J, Offner F, et al. Enteric nervous system alpha-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology. 2015;85(20):1761\u20138.","journal-title":"Neurology"},{"issue":"6","key":"1073_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016;79(6):940\u20139.","journal-title":"Ann Neurol"},{"issue":"10","key":"1073_CR8","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N, et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077\u201388.","journal-title":"Brain"},{"issue":"21","key":"1073_CR9","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1212\/WNL.0000000000003961","volume":"88","author":"B Liu","year":"2017","unstructured":"Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. 2017;88(21):1996\u20132002.","journal-title":"Neurology"},{"issue":"4","key":"1073_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sorensen HT. Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann Neurol. 2015;78(4):522\u20139.","journal-title":"Ann Neurol"},{"issue":"4","key":"1073_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson\u2019s Disease. Neuron. 2019;103(4):627-41e7.","journal-title":"Neuron"},{"issue":"2","key":"1073_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","volume":"19","author":"JF Cryan","year":"2020","unstructured":"Cryan JF, O\u2019Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179\u201394.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1073_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VTE Aho","year":"2021","unstructured":"Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol Neurodegener. 2021;16(1):6.","journal-title":"Mol Neurodegener"},{"issue":"12","key":"1073_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028032","volume":"6","author":"CB Forsyth","year":"2011","unstructured":"Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease. PLoS ONE. 2011;6(12): e28032.","journal-title":"PLoS ONE"},{"key":"1073_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fnins.2019.00992","volume":"13","author":"A Mulak","year":"2019","unstructured":"Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson\u2019s disease. Front Neurosci. 2019;13:992.","journal-title":"Front Neurosci"},{"issue":"5","key":"1073_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","volume":"68","author":"P Perez-Pardo","year":"2019","unstructured":"Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, et al. Role of TLR4 in the gut-brain axis in Parkinson\u2019s disease: a translational study from men to mice. Gut. 2019;68(5):829\u201343.","journal-title":"Gut"},{"key":"1073_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","volume":"50","author":"A Schwiertz","year":"2018","unstructured":"Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Burmann J, Fassbender K, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;50:104\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1073_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7(1):27.","journal-title":"NPJ Parkinsons Dis."},{"issue":"7766","key":"1073_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","volume":"571","author":"D Matheoud","year":"2019","unstructured":"Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, et al. Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1(-\/-) mice. Nature. 2019;571(7766):565\u20139.","journal-title":"Nature"},{"issue":"6","key":"1073_CR20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell. 2016;167(6):1469-80e12.","journal-title":"Cell"},{"key":"1073_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: Gut microbiota, glial reaction and TLR4\/TNF-alpha signaling pathway. Brain Behav Immun. 2018;70:48\u201360.","journal-title":"Brain Behav Immun"},{"issue":"6","key":"1073_CR22","doi-asserted-by":"publisher","first-page":"fcad285","DOI":"10.1093\/braincomms\/fcad285","volume":"5","author":"MJ Hurley","year":"2023","unstructured":"Hurley MJ, Menozzi E, Koletsi S, Bates R, Gegg ME, Chau KY, et al. alpha-Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells: an in vitro proof of concept study. Brain Commun. 2023;5(6):fcad285.","journal-title":"Brain Commun."},{"issue":"1","key":"1073_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1757-4749-4-16","volume":"4","author":"R Saad","year":"2012","unstructured":"Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012;4(1):16.","journal-title":"Gut Pathog."},{"issue":"10423","key":"1073_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","volume":"403","author":"T Foltynie","year":"2024","unstructured":"Foltynie T, Bruno V, Fox S, Kuhn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson\u2019s disease. Lancet. 2024;403(10423):305\u201324.","journal-title":"Lancet"},{"issue":"5","key":"1073_CR25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HC, Aureli F, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol. 2023;30(5):1465\u201380.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1073_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","volume":"8","author":"M Beckers","year":"2022","unstructured":"Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):56.","journal-title":"NPJ Parkinsons Dis."},{"key":"1073_CR27","doi-asserted-by":"publisher","first-page":"1151850","DOI":"10.3389\/fnagi.2023.1151850","volume":"15","author":"G Hey","year":"2023","unstructured":"Hey G, Nair N, Klann E, Gurrala A, Safarpour D, Mai V, et al. Therapies for Parkinson\u2019s disease and the gut microbiome: evidence for bidirectional connection. Front Aging Neurosci. 2023;15:1151850.","journal-title":"Front Aging Neurosci."},{"issue":"7","key":"1073_CR28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.apsb.2020.09.013","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Han Y, Huang W, Jin M, Gao Z. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B. 2021;11(7):1789\u2013812.","journal-title":"Acta Pharm Sin B."},{"issue":"1","key":"1073_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12915-020-00876-3","volume":"18","author":"SP van Kessel","year":"2020","unstructured":"van Kessel SP, de Jong HR, Winkel SL, van Leeuwen SS, Nelemans SA, Permentier H, et al. Gut bacterial deamination of residual levodopa medication for Parkinson\u2019s disease. BMC Biol. 2020;18(1):137.","journal-title":"BMC Biol"},{"key":"1073_CR30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3389\/fneur.2019.01087","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, El Aidy S. Contributions of Gut bacteria and diet to drug pharmacokinetics in the treatment of Parkinson\u2019s disease. Front Neurol. 2019;10:1087.","journal-title":"Front Neurol"},{"issue":"1","key":"1073_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/jpet.114.216317","volume":"351","author":"SM Camargo","year":"2014","unstructured":"Camargo SM, Vuille-dit-Bille RN, Mariotta L, Ramadan T, Huggel K, Singer D, et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson\u2019s disease. J Pharmacol Exp Ther. 2014;351(1):114\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1073_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41531-023-00541-w","volume":"9","author":"C Rusch","year":"2023","unstructured":"Rusch C, Flanagan R, Suh H, Subramanian I. To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):98.","journal-title":"NPJ Parkinsons Dis."},{"issue":"10","key":"1073_CR33","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/mds.21003","volume":"21","author":"M Barichella","year":"2006","unstructured":"Barichella M, Marczewska A, De Notaris R, Vairo A, Baldo C, Mauri A, et al. Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson\u2019s disease. Mov Disord. 2006;21(10):1682\u20137.","journal-title":"Mov Disord"},{"issue":"2","key":"1073_CR34","first-page":"135","volume":"27","author":"HC Guldberg","year":"1975","unstructured":"Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27(2):135\u2013206.","journal-title":"Pharmacol Rev"},{"key":"1073_CR35","doi-asserted-by":"publisher","unstructured":"Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019;364(6445):eaau6323. https:\/\/doi.org\/10.1126\/science.aau6323. PMID: 31196984; PMCID: PMC7745125.","DOI":"10.1126\/science.aau6323"},{"issue":"5284","key":"1073_CR36","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/229414a0","volume":"229","author":"M Sandler","year":"1971","unstructured":"Sandler M, Goodwin BL, Ruthven CR. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Nature. 1971;229(5284):414\u20135.","journal-title":"Nature"},{"issue":"1","key":"1073_CR37","first-page":"160","volume":"186","author":"BR Goldin","year":"1973","unstructured":"Goldin BR, Peppercorn MA, Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 1973;186(1):160\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1073_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat Commun. 2019;10(1):310.","journal-title":"Nat Commun"},{"issue":"22","key":"1073_CR39","doi-asserted-by":"publisher","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","volume":"99","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, He X, Mo C, Liu X, Li J, Yan Z, et al. Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease. Neurology. 2022;99(22):e2443\u201353.","journal-title":"Neurology"},{"issue":"6143","key":"1073_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1235872","volume":"341","author":"HJ Haiser","year":"2013","unstructured":"Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295\u20138.","journal-title":"Science"},{"issue":"3","key":"1073_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000103892","volume":"25","author":"A Gasbarrini","year":"2007","unstructured":"Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007;25(3):237\u201340.","journal-title":"Dig Dis"},{"key":"1073_CR42","doi-asserted-by":"crossref","unstructured":"Losurdo G, Salvatore D'Abramo F, Indellicati G, Lillo C, Ierardi E, Di Leo A. The influence of small intestinal bacterial overgrowth in digestive and extra-intestinal disorders. Int J Mol Sci. 2020;21(10).","DOI":"10.3390\/ijms21103531"},{"issue":"9","key":"1073_CR43","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, et al. The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov Disord. 2013;28(9):1241\u20139.","journal-title":"Mov Disord"},{"issue":"5","key":"1073_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","volume":"20","author":"AH Tan","year":"2014","unstructured":"Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(5):535\u201340.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1073_CR45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.23566","volume":"26","author":"M Gabrielli","year":"2011","unstructured":"Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov Disord. 2011;26(5):889\u201392.","journal-title":"Mov Disord"},{"key":"1073_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2018.04.003","volume":"54","author":"JA Vizcarra","year":"2018","unstructured":"Vizcarra JA, Wilson-Perez HE, Fasano A, Espay AJ. Small intestinal bacterial overgrowth in Parkinson\u2019s disease: tribulations of a trial. Parkinsonism Relat Disord. 2018;54:110\u20132.","journal-title":"Parkinsonism Relat Disord"},{"key":"1073_CR47","doi-asserted-by":"crossref","unstructured":"Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter. 2017;22(5).","DOI":"10.1111\/hel.12398"},{"key":"1073_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.parkreldis.2017.11.331","volume":"47","author":"HK Huang","year":"2018","unstructured":"Huang HK, Wang JH, Lei WY, Chen CL, Chang CY, Liou LS. Helicobacter pylori infection is associated with an increased risk of Parkinson\u2019s disease: a population-based retrospective cohort study. Parkinsonism Relat Disord. 2018;47:26\u201331.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1073_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.parkreldis.2014.12.009","volume":"21","author":"AH Tan","year":"2015","unstructured":"Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(3):221\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1073_CR50","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ana.1267","volume":"50","author":"M Pierantozzi","year":"2001","unstructured":"Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, et al. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson\u2019s disease patients. Ann Neurol. 2001;50(5):686\u20137.","journal-title":"Ann Neurol"},{"issue":"1","key":"1073_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s100720170061","volume":"22","author":"M Pierantozzi","year":"2001","unstructured":"Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson\u2019s disease patients. Neurol Sci. 2001;22(1):89\u201391.","journal-title":"Neurol Sci"},{"issue":"12","key":"1073_CR52","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","volume":"66","author":"M Pierantozzi","year":"2006","unstructured":"Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66(12):1824\u20139.","journal-title":"Neurology"},{"issue":"12","key":"1073_CR53","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/mds.22190","volume":"23","author":"WY Lee","year":"2008","unstructured":"Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson\u2019s disease. Mov Disord. 2008;23(12):1696\u2013700.","journal-title":"Mov Disord"},{"issue":"2","key":"1073_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3988\/jcn.2017.13.2.181","volume":"13","author":"KR Mridula","year":"2017","unstructured":"Mridula KR, Borgohain R, Chandrasekhar Reddy V, Bandaru V, Suryaprabha T. Association of Helicobacter pylori with Parkinson\u2019s Disease. J Clin Neurol. 2017;13(2):181\u20136.","journal-title":"J Clin Neurol"},{"issue":"12","key":"1073_CR55","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/mds.28248","volume":"35","author":"AH Tan","year":"2020","unstructured":"Tan AH, Lim SY, Mahadeva S, Loke MF, Tan JY, Ang BH, et al. Helicobacter pylori eradication in Parkinson\u2019s disease: a randomized placebo-controlled trial. Mov Disord. 2020;35(12):2250\u201360.","journal-title":"Mov Disord"},{"issue":"4","key":"1073_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WNF.0000000000000037","volume":"37","author":"E Narozanska","year":"2014","unstructured":"Narozanska E, Bialecka M, Adamiak-Giera U, Gawronska-Szklarz B, Soltan W, Schinwelski M, et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol. 2014;37(4):96\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1073_CR57","first-page":"112","volume":"3","author":"AC Dukowicz","year":"2007","unstructured":"Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112\u201322.","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"10","key":"1073_CR58","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1211\/jpp\/61.10.0005","volume":"61","author":"M Niehues","year":"2009","unstructured":"Niehues M, Hensel A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J Pharm Pharmacol. 2009;61(10):1303\u20137.","journal-title":"J Pharm Pharmacol"},{"key":"1073_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.729961","volume":"12","author":"JF Baizabal-Carvallo","year":"2021","unstructured":"Baizabal-Carvallo JF, Alonso-Juarez M, Fekete R. Intestinal decontamination therapy for dyskinesia and motor fluctuations in Parkinson\u2019s disease. Front Neurol. 2021;12: 729961.","journal-title":"Front Neurol"},{"key":"1073_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.574529","volume":"12","author":"N Palacios","year":"2021","unstructured":"Palacios N, Hannoun A, Flahive J, Ward D, Goostrey K, Deb A, Smith KM. Effect of levodopa initiation on the gut microbiota in Parkinson\u2019s disease. Front Neurol. 2021;12: 574529.","journal-title":"Front Neurol"},{"issue":"1","key":"1073_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/mds.27105","volume":"33","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart A, Pandey U, Wicke T, Sixel-Doring F, Janzen A, Sittig-Wiegand E, et al. The nasal and gut microbiome in Parkinson\u2019s disease and idiopathic rapid eye movement sleep behavior disorder. Mo Disord. 2018;33(1):88\u201398.","journal-title":"Mo Disord"},{"key":"1073_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41531-019-0100-x","volume":"5","author":"S Weis","year":"2019","unstructured":"Weis S, Schwiertz A, Unger MM, Becker A, Fassbender K, Ratering S, et al. Effect of Parkinson\u2019s disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis. 2019;5:28.","journal-title":"NPJ Parkinsons Dis."},{"issue":"4","key":"1073_CR63","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.14644","volume":"28","author":"M Melis","year":"2021","unstructured":"Melis M, Vascellari S, Santoru ML, Oppo V, Fabbri M, Sarchioto M, et al. Gut microbiota and metabolome distinctive features in Parkinson disease: focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur J Neurol. 2021;28(4):1198\u2013209.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1073_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1073_CR65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s00415-021-10657-9","volume":"269","author":"M Lubomski","year":"2022","unstructured":"Lubomski M, Xu X, Holmes AJ, Yang JYH, Sue CM, Davis RL. The impact of device-assisted therapies on the gut microbiome in Parkinson\u2019s disease. J Neurol. 2022;269(2):780\u201395.","journal-title":"J Neurol"},{"issue":"4","key":"1073_CR66","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1128\/aem.61.4.1669-1672.1995","volume":"61","author":"MM Benjamin","year":"1995","unstructured":"Benjamin MM, Datta AR. Acid tolerance of enterohemorrhagic Escherichia coli. Appl Environ Microbiol. 1995;61(4):1669\u201372.","journal-title":"Appl Environ Microbiol"},{"issue":"3","key":"1073_CR67","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/mdc3.13417","volume":"9","author":"Y Yamanishi","year":"2022","unstructured":"Yamanishi Y, Choudhury ME, Yoshida A, Hosokawa Y, Miyaue N, Tada S, et al. Impact of Intestinal Bacteria on Levodopa Pharmacokinetics in LCIG Therapy. Mov Disord Clin Pract. 2022;9(3):362\u20138.","journal-title":"Mov Disord Clin Pract."},{"issue":"3","key":"1073_CR68","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mds.27581","volume":"34","author":"M Barichella","year":"2019","unstructured":"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Mov Disord. 2019;34(3):396\u2013405.","journal-title":"Mov Disord"},{"key":"1073_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Burmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66\u201372.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1073_CR70","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739\u201349.","journal-title":"Mov Disord"},{"key":"1073_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.11.020","volume":"70","author":"D Grun","year":"2020","unstructured":"Grun D, Zimmer VC, Kauffmann J, Spiegel J, Dillmann U, Schwiertz A, et al. Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;70:20\u20132.","journal-title":"Parkinsonism Relat Disord"},{"key":"1073_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.837019","volume":"12","author":"SC Fu","year":"2022","unstructured":"Fu SC, Lee CH, Hsieh YC, Wu PH, Lin SH, Wang H. A pilot study exploring the association of entacapone, gut microbiota, and the subsequent side effects in patients with Parkinson\u2019s disease. Front Cell Infect Microbiol. 2022;12: 837019.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1073_CR73","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.01191-21","volume":"7","author":"SP van Kessel","year":"2022","unstructured":"van Kessel SP, Bullock A, van Dijk G, El Aidy S. Parkinson\u2019s disease medication alters small intestinal motility and microbiota composition in healthy rats. mSystems. 2022;7(1): e0119121.","journal-title":"mSystems."},{"key":"1073_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-020-0112-6","volume":"6","author":"ZD Wallen","year":"2020","unstructured":"Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 2020;6:11.","journal-title":"NPJ Parkinsons Dis."},{"issue":"1","key":"1073_CR75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-021-00260-0","volume":"7","author":"SP van Kessel","year":"2021","unstructured":"van Kessel SP, Auvinen P, Scheperjans F, El Aidy S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease. NPJ Parkinsons Dis. 2021;7(1):115.","journal-title":"NPJ Parkinsons Dis."},{"key":"1073_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.875261","volume":"14","author":"M Lubomski","year":"2022","unstructured":"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL, Sue CM. The gut microbiome in Parkinson\u2019s disease: a longitudinal study of the impacts on disease progression and the use of device-assisted therapies. Front Aging Neurosci. 2022;14: 875261.","journal-title":"Front Aging Neurosci."},{"key":"1073_CR77","doi-asserted-by":"crossref","unstructured":"Varesi A, Campagnoli LIM, Fahmideh F, Pierella E, Romeo M, Ricevuti G, et al. The interplay between gut microbiota and Parkinson's disease: implications on diagnosis and treatment. Int J Mol Sci. 2022;23(20).","DOI":"10.3390\/ijms232012289"},{"issue":"5","key":"1073_CR78","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1212\/WNL.0000000000007858","volume":"93","author":"M Barichella","year":"2019","unstructured":"Barichella M, Cereda E, Pinelli G, Iorio L, Caroli D, Masiero I, et al. Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. Neurology. 2019;93(5):e485\u201396.","journal-title":"Neurology"},{"key":"1073_CR79","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clnesp.2022.01.023","volume":"48","author":"S Coe","year":"2022","unstructured":"Coe S, Andreoli D, George M, Collett J, Reed A, Cossington J, et al. A feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue and fatigability in people with Parkinson\u2019s (pwP). Clin Nutr ESPEN. 2022;48:68\u201373.","journal-title":"Clin Nutr ESPEN."},{"issue":"6","key":"1073_CR80","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.clnu.2014.12.007","volume":"34","author":"A Cucca","year":"2015","unstructured":"Cucca A, Mazzucco S, Bursomanno A, Antonutti L, Di Girolamo FG, Pizzolato G, et al. Amino acid supplementation in l-dopa treated Parkinson\u2019s disease patients. Clin Nutr. 2015;34(6):1189\u201394.","journal-title":"Clin Nutr"},{"issue":"2\u20133","key":"1073_CR81","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","volume":"111","author":"TM da Silva","year":"2008","unstructured":"da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC. Depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2\u20133):351\u20139.","journal-title":"J Affect Disord"},{"issue":"1\u20134","key":"1073_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000333790","volume":"10","author":"J DiFrancisco-Donoghue","year":"2012","unstructured":"DiFrancisco-Donoghue J, Lamberg EM, Rabin E, Elokda A, Fazzini E, Werner WG. Effects of exercise and B vitamins on homocysteine and glutathione in Parkinson\u2019s disease: a randomized trial. Neurodegener Dis. 2012;10(1\u20134):127\u201334.","journal-title":"Neurodegener Dis"},{"key":"1073_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102366","volume":"50","author":"Z Paknahad","year":"2020","unstructured":"Paknahad Z, Sheklabadi E, Derakhshan Y, Bagherniya M, Chitsaz A. The effect of the Mediterranean diet on cognitive function in patients with Parkinson\u2019s disease: a randomized clinical controlled trial. Complement Ther Med. 2020;50: 102366.","journal-title":"Complement Ther Med"},{"issue":"2","key":"1073_CR84","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/1028415X.2020.1751509","volume":"25","author":"Z Paknahad","year":"2022","unstructured":"Paknahad Z, Sheklabadi E, Moravejolahkami AR, Chitsaz A, Hassanzadeh A. The effects of Mediterranean diet on severity of disease and serum Total Antioxidant Capacity (TAC) in patients with Parkinson\u2019s disease: a single center, randomized controlled trial. Nutr Neurosci. 2022;25(2):313\u201320.","journal-title":"Nutr Neurosci"},{"issue":"8","key":"1073_CR85","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.27390","volume":"33","author":"MCL Phillips","year":"2018","unstructured":"Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson\u2019s disease: A pilot randomized controlled trial. Mov Disord. 2018;33(8):1306\u201314.","journal-title":"Mov Disord"},{"issue":"9","key":"1073_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053336","volume":"11","author":"C Rusch","year":"2021","unstructured":"Rusch C, Beke M, Tucciarone L, Dixon K, Nieves C Jr, Mai V, et al. Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson\u2019s disease (the MEDI-PD study): study protocol for a randomised controlled trial. BMJ Open. 2021;11(9): e053336.","journal-title":"BMJ Open"},{"issue":"14","key":"1073_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12883-014-0212-1","volume":"18","author":"JM Sheard","year":"2014","unstructured":"Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK. Improved nutritional status is related to improved quality of life in Parkinson\u2019s disease. BMC Neurol. 2014;18(14):212.","journal-title":"BMC Neurol"},{"key":"1073_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuint.2017.03.014","volume":"108","author":"M Taghizadeh","year":"2017","unstructured":"Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017;108:183\u20139.","journal-title":"Neurochem Int"},{"issue":"367","key":"1073_CR89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2016.05.056","volume":"15","author":"P Tosukhowong","year":"2016","unstructured":"Tosukhowong P, Boonla C, Dissayabutra T, Kaewwilai L, Muensri S, Chotipanich C, et al. Biochemical and clinical effects of Whey protein supplementation in Parkinson\u2019s disease: a pilot study. J Neurol Sci. 2016;15(367):162\u201370.","journal-title":"J Neurol Sci"},{"issue":"434","key":"1073_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120166","volume":"15","author":"RJ Solch","year":"2022","unstructured":"Solch RJ, Aigbogun JO, Voyiadjis AG, Talkington GM, Darensbourg RM, O\u2019Connell S, et al. Mediterranean diet adherence, gut microbiota, and Alzheimer\u2019s or Parkinson\u2019s disease risk: a systematic review. J Neurol Sci. 2022;15(434): 120166.","journal-title":"J Neurol Sci"},{"key":"1073_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.794640","volume":"12","author":"C Rusch","year":"2021","unstructured":"Rusch C, Beke M, Tucciarone L, Nieves C Jr, Ukhanova M, Tagliamonte MS, et al. Mediterranean diet adherence in people with Parkinson\u2019s disease reduces constipation symptoms and changes fecal microbiota after a 5-week single-arm pilot study. Front Neurol. 2021;12: 794640.","journal-title":"Front Neurol"},{"key":"1073_CR92","doi-asserted-by":"crossref","unstructured":"Pietrzak D, Kasperek K, Rekawek P, Piatkowska-Chmiel I. The therapeutic role of ketogenic diet in neurological disorders. Nutrients. 2022;14(9).","DOI":"10.3390\/nu14091952"},{"issue":"4","key":"1073_CR93","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1212\/01.WNL.0000152046.11390.45","volume":"64","author":"TB Vanitallie","year":"2005","unstructured":"Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005;64(4):728\u201330.","journal-title":"Neurology"},{"key":"1073_CR94","doi-asserted-by":"crossref","unstructured":"Hegelmaier T, Lebbing M, Duscha A, Tomaske L, Tonges L, Holm JB, et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease. Cells. 2020;9(2).","DOI":"10.3390\/cells9020376"},{"issue":"3","key":"1073_CR95","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.108170","volume":"19","author":"P Mirmiran","year":"2021","unstructured":"Mirmiran P, Bahadoran Z, Gaeini Z. Common limitations and challenges of dietary clinical trials for translation into clinical practices. Int J Endocrinol Metab. 2021;19(3): e108170.","journal-title":"Int J Endocrinol Metab."},{"issue":"8","key":"1073_CR96","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","volume":"14","author":"GR Gibson","year":"2017","unstructured":"Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491\u2013502.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"1073_CR97","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1007\/s13197-015-1921-1","volume":"52","author":"KR Pandey","year":"2015","unstructured":"Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics\u2014a review. J Food Sci Technol. 2015;52(12):7577\u201387.","journal-title":"J Food Sci Technol"},{"key":"1073_CR98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","volume":"10","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas D, De la Fuente MK, Landskron G, Gonzalez MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.","journal-title":"Front Immunol"},{"key":"1073_CR99","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3389\/fneur.2019.00663","volume":"10","author":"TM Cantu-Jungles","year":"2019","unstructured":"Cantu-Jungles TM, Rasmussen HE, Hamaker BR. Potential of prebiotic butyrogenic fibers in Parkinson\u2019s disease. Front Neurol. 2019;10:663.","journal-title":"Front Neurol"},{"issue":"1","key":"1073_CR100","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41467-023-36497-x","volume":"14","author":"DA Hall","year":"2023","unstructured":"Hall DA, Voigt RM, Cantu-Jungles TM, Hamaker B, Engen PA, Shaikh M, et al. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson\u2019s disease participants. Nat Commun. 2023;14(1):926.","journal-title":"Nat Commun"},{"issue":"5","key":"1073_CR101","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","volume":"15","author":"R Astarloa","year":"1992","unstructured":"Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992;15(5):375\u201380.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"1073_CR102","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/mds.870120617","volume":"12","author":"W Ashraf","year":"1997","unstructured":"Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson\u2019s disease: objective assessment and response to psyllium. Mov Disord. 1997;12(6):946\u201351.","journal-title":"Mov Disord"},{"issue":"2","key":"1073_CR103","first-page":"274","volume":"20","author":"A Becker","year":"2022","unstructured":"Becker A, Schmartz GP, Groger L, Grammes N, Galata V, Philippeit H, et al. Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson\u2019s disease\u2014the RESISTA-PD Trial. Genom ProteomBioinform. 2022;20(2):274\u201387.","journal-title":"Genom ProteomBioinform"},{"issue":"8","key":"1073_CR104","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506\u201314.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1073_CR105","first-page":"117","volume":"57","author":"E Cassani","year":"2011","unstructured":"Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, Barichella M. Use of probiotics for the treatment of constipation in Parkinson\u2019s disease patients. Minerva Gastroenterol Dietol. 2011;57(2):117\u201321.","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"12","key":"1073_CR106","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","volume":"87","author":"M Barichella","year":"2016","unstructured":"Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. 2016;87(12):1274\u201380.","journal-title":"Neurology"},{"key":"1073_CR107","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.parkreldis.2022.08.022","volume":"103","author":"Y Du","year":"2022","unstructured":"Du Y, Li Y, Xu X, Li R, Zhang M, Cui Y, et al. Probiotics for constipation and gut microbiota in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2022;103:92\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"1073_CR108","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/CIA.S106284","volume":"11","author":"D Georgescu","year":"2016","unstructured":"Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson\u2019s disease: is there hope? Clin Interv Aging. 2016;11:1601\u20138.","journal-title":"Clin Interv Aging"},{"issue":"12","key":"1073_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244680","volume":"15","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ, et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson\u2019s disease: a randomised controlled trial. PLoS ONE. 2020;15(12): e0244680.","journal-title":"PLoS ONE"},{"issue":"1","key":"1073_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-022-00327-6","volume":"8","author":"H Sun","year":"2022","unstructured":"Sun H, Zhao F, Liu Y, Ma T, Jin H, Quan K, et al. Probiotics synergized with conventional regimen in managing Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):62.","journal-title":"NPJ Parkinsons Dis."},{"issue":"3","key":"1073_CR111","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","volume":"38","author":"OR Tamtaji","year":"2019","unstructured":"Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, et al. Clinical and metabolic response to probiotic administration in people with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(3):1031\u20135.","journal-title":"Clin Nutr"},{"issue":"5","key":"1073_CR112","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1212\/WNL.0000000000010998","volume":"96","author":"AH Tan","year":"2021","unstructured":"Tan AH, Lim SY, Chong KK, Manap MA, Hor JW, Lim JL, et al. Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study. Neurology. 2021;96(5):e772\u201382.","journal-title":"Neurology"},{"issue":"15","key":"1073_CR113","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1039\/D3FO00728F","volume":"14","author":"X Yang","year":"2023","unstructured":"Yang X, He X, Xu S, Zhang Y, Mo C, Lai Y, et al. Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson\u2019s disease. Food Funct. 2023;14(15):6828\u201339.","journal-title":"Food Funct"},{"issue":"7","key":"1073_CR114","first-page":"289","volume":"21","author":"S Borzabadi","year":"2018","unstructured":"Borzabadi S, Oryan S, Eidi A, Aghadavod E, Daneshvar Kakhaki R, Tamtaji OR, et al. The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson\u2019s disease: a randomized, double-blind placebocontrolled, trial. Arch Iran Med. 2018;21(7):289\u201395.","journal-title":"Arch Iran Med"},{"issue":"2","key":"1073_CR115","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"1","key":"1073_CR116","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40168-021-01107-9","volume":"9","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Ning J, Bao XQ, Shang M, Ma J, Li G, Zhang D. Fecal microbiota transplantation protects rotenone-induced Parkinson\u2019s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021;9(1):226.","journal-title":"Microbiome."},{"key":"1073_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100642","volume":"29\u201330","author":"SMD Baunwall","year":"2020","unstructured":"Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;29\u201330: 100642.","journal-title":"EClinicalMedicine."},{"issue":"1","key":"1073_CR118","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","volume":"20","author":"XY Kuai","year":"2021","unstructured":"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, et al. Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation. Microb Cell Fact. 2021;20(1):98.","journal-title":"Microb Cell Fact"},{"issue":"35","key":"1073_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022035","volume":"99","author":"LJ Xue","year":"2020","unstructured":"Xue LJ, Yang XZ, Tong Q, Shen P, Ma SJ, Wu SN, et al. Fecal microbiota transplantation therapy for Parkinson\u2019s disease: a preliminary study. Medicine (Baltimore). 2020;99(35): e22035.","journal-title":"Medicine (Baltimore)"},{"key":"1073_CR120","doi-asserted-by":"publisher","first-page":"1104759","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL DuPont","year":"2023","unstructured":"DuPont HL, Suescun J, Jiang ZD, Brown EL, Essigmann HT, Alexander AS, et al. Fecal microbiota transplantation in Parkinson\u2019s disease\u2014a randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023;14:1104759.","journal-title":"Front Neurol"},{"key":"1073_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106791","volume":"207","author":"A Segal","year":"2021","unstructured":"Segal A, Zlotnik Y, Moyal-Atias K, Abuhasira R, Ifergane G. Fecal microbiota transplant as a potential treatment for Parkinson\u2019s disease\u2014a case series. Clin Neurol Neurosurg. 2021;207: 106791.","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"1073_CR122","doi-asserted-by":"publisher","first-page":"e071766","DOI":"10.1136\/bmjopen-2023-071766","volume":"13","author":"KE Vendrik","year":"2023","unstructured":"Vendrik KE, Chernova VO, Kuijper EJ, Terveer EM, van Hilten JJ, Contarino MF. Safety and feasibility of faecal microbiota transplantation for patients with Parkinson\u2019s disease: a protocol for a self-controlled interventional donor-FMT pilot study. BMJ Open. 2023;13(10):e071766.","journal-title":"BMJ Open"},{"issue":"3","key":"1073_CR123","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/jclinpath-2015-202976","volume":"69","author":"A Di Cerbo","year":"2016","unstructured":"Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69(3):187\u2013203.","journal-title":"J Clin Pathol"},{"issue":"11","key":"1073_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187307","volume":"12","author":"T Minato","year":"2017","unstructured":"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, Hirayama M. Progression of Parkinson\u2019s disease is associated with gut dysbiosis: two-year follow-up study. PLoS ONE. 2017;12(11): e0187307.","journal-title":"PLoS ONE"},{"key":"1073_CR125","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","volume":"44","author":"VTE Aho","year":"2019","unstructured":"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Gut microbiota in Parkinson\u2019s disease: temporal stability and relations to disease progression. EBioMedicine. 2019;44:691\u2013707.","journal-title":"EBioMedicine"},{"issue":"1","key":"1073_CR126","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JPD-202297","volume":"11","author":"R Cilia","year":"2021","unstructured":"Cilia R, Piatti M, Cereda E, Bolliri C, Caronni S, Ferri V, et al. Does Gut microbiota influence the course of Parkinson\u2019s disease? A 3-year prospective exploratory study in de novo patients. J Parkinsons Dis. 2021;11(1):159\u201370.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1073_CR127","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1038\/s41467-023-38248-4","volume":"14","author":"B Huang","year":"2023","unstructured":"Huang B, Chau SWH, Liu Y, Chan JWY, Wang J, Ma SL, et al. Gut microbiome dysbiosis across early Parkinson\u2019s disease, REM sleep behavior disorder and their first-degree relatives. Nat Commun. 2023;14(1):2501.","journal-title":"Nat Commun"},{"issue":"3","key":"1073_CR128","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ana.26719","volume":"94","author":"N Palacios","year":"2023","unstructured":"Palacios N, Wilkinson J, Bjornevik K, Schwarzschild MA, McIver L, Ascherio A, Huttenhower C. Metagenomics of the gut microbiome in Parkinson\u2019s disease: prodromal changes. Ann Neurol. 2023;94(3):486\u2013501.","journal-title":"Ann Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01073-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:10:26Z","timestamp":1713460226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01073-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01073-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"14 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded in part by Aligning Science Across Parkinson\u2019s (Grant number: ASAP-000420) through the Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) and by the EU Joint Programme\u2013Neurodegenerative Research (JPND) through the MRC grant code MR\/T046007\/1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EM has received honoraria for a sponsored symposium from OMNIX PHARMA S.L. AHVS does not have any conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"EM conceived the manuscript and wrote the first draft. AHVS conceived and reviewed the manuscript. All authors read and approved the final version of the manuscript, and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}